The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
Elevance Health (ELV) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.99 per share. This compares to earnings of $9.04 per share a year ago.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The healthcare sector is often considered a defensive play, with healthcare stocks to buy offering stability and growth potential even during economic downturns. The sector's strength is driven by an aging global population, rising healthcare expenditures, and advancements in medical technology.
Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.
While it's never a bad time to look for healthcare stocks to buy, the privatization of Medicare has created some very prosperous businesses. As a result, it's not necessarily great for consumers.